Usana Health Sciences/$USNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Usana Health Sciences
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Ticker
$USNA
Sector
Primary listing
NYSE
Industry
Personal Care Products
Headquarters
Employees
1,700
ISIN
US90328M1071
Website
USNA Metrics
BasicAdvanced
$570M
16.86
$1.82
0.64
-
Price and volume
Market cap
$570M
Beta
0.64
52-week high
$47.91
52-week low
$23.10
Average daily volume
143K
Financial strength
Current ratio
2.048
Quick ratio
1.307
Total debt to equity
3.939
Interest coverage (TTM)
89.57%
Profitability
EBITDA (TTM)
72.338
Gross margin (TTM)
80.53%
Net profit margin (TTM)
3.98%
Operating margin (TTM)
6.54%
Effective tax rate (TTM)
47.24%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
5.21%
Return on equity (TTM)
6.42%
Valuation
Price to earnings (TTM)
16.858
Price to revenue (TTM)
0.667
Price to book
1.1
Price to tangible book (TTM)
2.45
Price to free cash flow (TTM)
11.894
Free cash flow yield (TTM)
8.41%
Free cash flow per share (TTM)
257.53%
Growth
Revenue change (TTM)
-2.69%
Earnings per share change (TTM)
-43.40%
3-year revenue growth (CAGR)
-8.70%
10-year revenue growth (CAGR)
0.57%
3-year earnings per share growth (CAGR)
-30.60%
10-year earnings per share growth (CAGR)
-4.84%
What the Analysts think about USNA
Analyst ratings (Buy, Hold, Sell) for Usana Health Sciences stock.
Bulls say / Bears say
USANA Health Sciences reported a 9.5% increase in revenue to $249.54 million in Q1 2025, surpassing analyst expectations of $243.04 million, indicating strong sales performance. (tradingview.com)
The company's acquisition of a 78.8% stake in Hiya Health for $205 million is expected to be immediately accretive to USANA's 2025 adjusted EBITDA, positioning it to capture growth in the children's health and wellness market. (directsellingnews.com)
USANA's reorganization of R&D and commercial teams aims to accelerate product development cycles, potentially leading to increased revenue growth by catering more effectively to market demands. (supplysidesj.com)
USANA's stock price declined by 24.9% in Q1 2025, reflecting investor concerns over the company's performance and market conditions. (directsellingnews.com)
The company reported a decrease in diluted earnings per share to $0.49 in Q1 2025, down from $0.86 in the same quarter the previous year, indicating a decline in profitability. (tradingview.com)
USANA's reliance on the Chinese market, which accounted for over 50% of its sales in Q2 2024, exposes the company to risks associated with economic uncertainties and regulatory challenges in that region. (supplysidesj.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
USNA Financial Performance
Revenues and expenses
USNA Earnings Performance
Company profitability
USNA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Usana Health Sciences stock?
Usana Health Sciences (USNA) has a market cap of $570M as of July 18, 2025.
What is the P/E ratio for Usana Health Sciences stock?
The price to earnings (P/E) ratio for Usana Health Sciences (USNA) stock is 16.86 as of July 18, 2025.
Does Usana Health Sciences stock pay dividends?
No, Usana Health Sciences (USNA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Usana Health Sciences dividend payment date?
Usana Health Sciences (USNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Usana Health Sciences?
Usana Health Sciences (USNA) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.